- Home
- CELC vs SSBK Comparison
CELC vs SSBK Comparison
Compare CELC & SSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- SSBK
- Stock Information
- Founded
- CELC 2011
- SSBK 2007
- Country
- CELC United States
- SSBK United States
- Employees
- CELC N/A
- SSBK N/A
- Industry
- CELC Medical Specialities
- SSBK Commercial Banks
- Sector
- CELC Health Care
- SSBK Finance
- Exchange
- CELC Nasdaq
- SSBK Nasdaq
- Market Cap
- CELC 391.0M
- SSBK N/A
- IPO Year
- CELC 2017
- SSBK 2021
- Fundamental
- Price
- CELC $10.11
- SSBK $35.85
- Analyst Decision
- CELC Strong Buy
- SSBK Buy
- Analyst Count
- CELC 6
- SSBK 1
- Target Price
- CELC $30.17
- SSBK $36.00
- AVG Volume (30 Days)
- CELC 248.4K
- SSBK 22.4K
- Earning Date
- CELC 03-31-2025
- SSBK 04-21-2025
- Dividend Yield
- CELC N/A
- SSBK 1.00%
- EPS Growth
- CELC N/A
- SSBK 3.77
- EPS
- CELC N/A
- SSBK 3.67
- Revenue
- CELC N/A
- SSBK $94,140,000.00
- Revenue This Year
- CELC $49.98
- SSBK $19.13
- Revenue Next Year
- CELC N/A
- SSBK $7.78
- P/E Ratio
- CELC N/A
- SSBK $9.86
- Revenue Growth
- CELC N/A
- SSBK 13.56
- 52 Week Low
- CELC $8.53
- SSBK $22.13
- 52 Week High
- CELC $22.04
- SSBK $39.16
- Technical
- Relative Strength Index (RSI)
- CELC 43.41
- SSBK 51.72
- Support Level
- CELC $9.98
- SSBK $32.11
- Resistance Level
- CELC $10.70
- SSBK $33.20
- Average True Range (ATR)
- CELC 0.68
- SSBK 0.72
- MACD
- CELC 0.06
- SSBK 0.11
- Stochastic Oscillator
- CELC 28.38
- SSBK 66.19
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.